Navigation Links
AEterna Zentaris Sells Quebec City Building for $7.1 million
Date:6/27/2008

All amounts are in U.S. dollars

QUEBEC CITY, June 27 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced it has completed the sale of its Quebec City property for a purchase price of $7.1 million, payable in cash. AEterna Zentaris also entered into a long-term lease agreement enabling the Company to continue occupying its current space for its Quebec City operations.

Juergen Ernst, Chairman and Interim President and CEO of AEterna Zentaris stated, "We are very pleased to have completed the sale of our Quebec City property. This is in line with our corporate strategy which includes divesting non-core assets to provide additional non-dilutive financing. The funds will be dedicated to our ongoing Phase 3 program with cetrorelix in benign prostatic hyperplasia."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process a
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
(Date:12/19/2014)... Mass. , Dec. 19, 2014 Decision ... market will grow at a 12 percent compound annual ... result of the aging population and the increasing adoption ... Latin America will also spur demand for ... of dental implant and periodontal treatments. Other ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , ATLANTA and LONDON, Sept. 10 ... biological medical device and cardiovascular tissue processing company, today announced the ... Matrix, which received CE mark approval in August 2009. BioFoam was ... supplemental measure to promote hemostasis (a complex process that stops bleeding) ...
... WATERTOWN, Mass., Sept. 10 Tetraphase Pharmaceuticals ... technology announced today that it will present three (3) ... and antibacterial activity of analogs from several novel classes ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in ...
... BALTIMORE, Sept. 10 Champions Biotechnology, Inc. ... oncology services division assists physicians by providing personalized treatment options ... with PinnacleCare , the pioneer and the ... , PinnacleCare will offer Champions, personalized oncology services ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... July 23, 2013 The goal of smart cities ... performance, efficiency and functionality. This is expressed through an ... of the overall city experience.  Cities are hoping to ... city projects to ultimately drive economic growth. Some key ...
... in the July issue of the Journal of ... super-infections like pneumonia with influenza. The research was led ... infectious disease specialist who is also chair of the ... Science Center and adjunct faculty at St. Jude Children,s ...
... NY. -- The use of central nervous system fetal ... cells for transplantation procedures aimed at restoring damage done ... tissue microbial contaminants have been known to cause brain ... team from Germany has developed a "washing" technique that ...
Cached Biology News:Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 2Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 3Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 4Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 5New protocol developed to decontaminate human fetal tissues used for cell transplantation 2
... for the rapid purification of linear 100 bp ... DNA band is excised from an,agarose gel and ... base of the column are a series of ... back while allowing DNA to selectively pass through ...
... is Tecans state-of-the-art software for all your ... scheduling in a single, scalable software package. ... consistent, simplifying the control of all Freedom ... Freedom EVO 100 with one liquid handling ...
...
... Isolation Kit provides all the reagents ... vesicle fraction. The isolation procedure involves ... synaptosomes, and differential centrifugation followed by ... also contains an antibody specific for ...
Biology Products: